Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

If You Invested $1,000 In Pfizer Stock At Its Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Benzinga

Latest data shows significant rise in Covid deaths in England and Wales for third week in a row

Deaths involving Covid-19 are up 13 per cent on last week, the latest data shows

Manchester Evening News

Covid booster gives long-lasting protection, study finds

'The longer-term protection against hospitalisation and death is perhaps the most important factor for future booster programmes'

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

Third Covid-19 vaccine dose offers ‘prolonged immune response’ – UK-wide study

The study compared immune responses to seven vaccines used as a booster 28 days after two initial doses.

The Independent UK

Pfizer Whale Trades For April 20

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 21 strange trades.

Benzinga

The Valneva COVID vaccine has been approved for use in the UK – here's what the evidence says

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new COVID vaccine. VLA2001 is manufactured by French pharmaceutical company Valneva for use in the UK and was approved on April 14 for use in adults between the ages of 18 and 50 for first and second doses.

The Conversation

Parents of kids under 5 still waiting for COVID shots

The demise of the federal transportation mask mandate was particularly jarring for many parents of children under five anxiously waiting for word on when COVID shots will become available to their kids.

Axios

Read news from The Economist, FT, and more,
with one subscription

Moderna says redesigned COVID-19 vaccine booster may work better against variants

Moderna’s updated COVID-19 booster shot shows even more efficiency against variants, the pharmaceutical company announced Tuesday, citing preliminary results from a trial.

Tribune News Service

Read Why Demand For Pfizer's COVID-19 Antiviral Therapy Is Unexpectedly Low: Reuters

Global demand for Pfizer Inc's (NYSE: PFE) Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions, a

Benzinga

Covid vaccination technology may be used as first heart attack ‘cure’

Protein produced by genetic code, mRNA, can create healthy new heart cells

Evening Standard

Covid vaccine developed in West Lothian is approved

It is the sixth Covid-19 vaccine to be granted an MHRA authorisation for use in Britain

Daily Record

J&J suspends COVID-19 vaccine sales forecast

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year

The Independent UK

Covid vaccine technology could be used for world’s first ‘cure for heart attacks’

Genetic codes called mRNAs produce proteins which can generate healthy heart cells

The Independent UK

Japan approves Novavax COVID-19 vaccine

Japan’s health ministry formally approved Novavax’s COVID-19 vaccine, a fourth foreign-developed tool to combat the infections

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Daily Record

Scientists developing 'blockbuster' heart attack cure using Covid vaccine tech

Researchers from King's College London are working on regenerating damaged hearts in the hope of developing a cure for heart attacks - with human trials set to begin within two years.

Benzinga

Two long COVID Patients Recover After Pfizer's Therapy; Side Effects, Safety Needs To Be Assessed: Reuters

Reuters reported that two patients found relief from long COVID after taking Pfizer Inc's (NYSE:PFE) antiviral Paxlovid, including a researcher who tested it on herself. Long COVID is estimated to affect up to 30% of people infected with the coronavirus. It can last for months. More than 200 symptoms have been associated with the…

Daily Mirror

Heart attack cure discovered thanks to new tech - which works like Covid vaccine

Researchers from King's College London have found a way to stimulate the creation of healthy heart cells - which can then be delivered to the muscle using the same technology used with the Moderna and Pfizer Covid vaccines

Wales Online

Covid vaccine boosters - why healthy people aren't being offered them yet

Should you get in line for a second booster ASAP?

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

California Democrats are delaying their vaccine plans. Here's why

SACRAMENTO, Calif. — California Democrats were moving toward requiring COVID-19 vaccines for students and keeping them from opting out of shots with personal belief exemptions.

Bristol Post

New Valneva covid vaccine and its links to Bristol explained

The UK has become the first major country to approve Valneva's vaccine against covid-19

Benzinga

Pfizer/BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Aged 5-11 Years

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from a Phase 2/3 trial of a 10 µg booster (third) dose of COVID-19 vaccine in children aged 5-11 years.

Axios

Pfizer says coronavirus booster dose increased immune response in children ages 5 to 11

If federal regulators verify the claims, children over the age of five could gain access to boosters.

The Independent UK

Pfizer to seek COVID booster for healthy 5- to 11-year-olds

Pfizer wants to expand its COVID-19 booster shots to healthy 5- to 11-year-olds

Reuters

Pfizer/BioNTech say booster dose increases protection vs Omicron in kids aged 5-11

A third dose of the COVID-19 vaccine from Pfizer Inc and BioNTech produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on Thursday.

Chicago Tribune

Commentary: Is a second booster for COVID-19 the right choice for you?

The Food and Drug Administration and the Centers for Disease Control and Prevention recently authorized a second booster shot of the Pfizer/BioNTech and Moderna COVID-19 vaccines for those age 50 and older. The recommendation follows a study out of Israel recently published in The New England Journal of Medicine.

1 … 56 57 58 59

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Food and Drug Administration

336 stories

Centers for Disease Control and Prevention

University of California

162 stories

JJ.

122 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.